Clinical Trials
52 trialsMaintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Indiana University
TICE
Institut Claudius Regaud
AflacST1502
Emory University
ASPIRE
Wake Forest University Health Sciences
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Indiana University
CD30 CAR for CD30+ NSGCT
UNC Lineberger Comprehensive Cancer Center
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
Sun Yat-sen University
Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor
Shandong First Medical University
DACT-GCT
National Cancer Institute, Slovakia
GERMAN
N.N. Petrov National Medical Research Center of Oncology
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
AVENTURINE
BioNTech SE
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Cedars-Sinai Medical Center
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
GAMMA
Barts & The London NHS Trust
UVA-Gen001
University of Virginia
A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
GAMEC-II
Queen Mary University of London
AcSé
UNICANCER
DISGCT
National Cancer Institute, Slovakia
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
St. Jude Children's Research Hospital
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Hoosier Cancer Research Network
Pazotest-01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
APACHE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
TIP
National Cancer Institute, Slovakia
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors
Ann & Robert H Lurie Children's Hospital of Chicago
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Indiana University
Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
Hospital Beatriz Ângelo
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Medical College of Wisconsin
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
Hoosier Cancer Research Network
Avelumab in Refractory Testicular Germ Cell Cancer.
National Cancer Institute, Slovakia
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
University of Texas Southwestern Medical Center
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Fondazione Michelangelo
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
University of Southern California
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Hoosier Cancer Research Network
Sunitinib Malate in Refractory Germ Cell Tumors
M.D. Anderson Cancer Center
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Indiana University
Everolimus in Refractory Testicular Germ Cell Cancer
National Cancer Institute, Slovakia
NET
Assistance Publique - Hôpitaux de Paris
RADIT
Hannover Medical School
IUCRO-0021
Indiana University
Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Indiana University
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer
British Columbia Cancer Agency
GCT
Fondation Wygrajmy Zdrowie